Release Date: 16-Jul-2024
Developed by Affimed, Acimtamig signifies a pioneering breakthrough in treating CD30-positive lymphomas. This bispecific antibody, currently in development, targets CD30-positive hematologic tumors. Fueled by Affimed’s groundbreaking ICE (innate cell engager) platform, Acimtamig stands as a first-in-class molecule, strategically activating the innate immune system for the precise elimination of CD30-positive malignancies. By acting as a bispecific engager, Acimtamig acts as a crucial bridge between immune cells and tumor cells, creating the necessary proximity for selective eradication. This revolutionary therapeutic approach places Acimtamig at the forefront of transformative treatments, ushering in a new era for CD30-positive lymphoma management.
Acimtamig, a tetravalent bispecific antibody, employs a unique mechanism to target CD30 and CD16A on NK cells, modulating the immune response and exerting antineoplastic effects. Upon administration, Acimtamig binds with CD16A on NK cells and engages with CD30 on tumor cells, activating NK cells and leading to antibody-dependent cellular cytotoxicity for tumor destruction. Recognizing CD30 overexpression in hematologic malignancies and CD16A specificity on NK cells, Acimtamig strategically enhances the body’s defense mechanisms against cancer cells, offering a promising avenue for immunomodulation and targeted antineoplastic activity. This novel approach positions Acimtamig as a potential game changer in cancer therapies.
Acimtamig is now being evaluated in the ongoing phase 2 LuminICE-203 trial, in conjunction with Artiva Biotherapeutics’ AlloNK (previously AB-101) natural killer (NK) cell therapy in patients with relapsed or refractory (r/r) Hodgkin Lymphoma. The FDA granted Acimtamig and AlloNK therapy fast track designation in September 2023 for the potential treatment of (r/r) Hodgkin lymphoma over showing exceptional efficacy as well as an acceptable safety profile in late-stage, multi-refractory, patients with r/r Hodgkin and non-Hodgkin lymphoma, alongside the potential to conquer current challenges in the treatment of r/r Hodgkin Lymphoma.
In conclusion, Acimtamig has the potential to be a game changer in the treatment of CD30-positive lymphoma. Ongoing clinical trials highlight its great potential, providing renewed hope for people dealing with these difficult disorders. Acimtamig’s fast track designation from the FDA not only recognizes its relevance, but also expedites its development, particularly in combination with AlloNK therapy. Acimtamig, as a ray of hope, illustrates a forward-thinking approach that has the potential to transform the therapeutic landscape for CD30-positive lymphomas, heralding a brighter future for patients in need of novel and effective treatment alternatives. Acimtamig’s novel strategy frames it as a possible game changer in cancer therapies.
For Clinical Trials Information Contact